Merrion Pharma in pact to evaluate GIPET technology
The agreement will evaluate the ability of Merrion Pharma’s patented GIPET technology to boost the bioavailablity of three of the ‘big pharma’ company’s compounds. Following the feasibility studies,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.